- Name: Sai-Lan Liu
- Title: Associate Chief Physician
- Email: liusl@sysucc.org.cn
- Phone:
Profile
Dr. Sai-Lan Liu is an associate chief physician of nasopharyngeal carcinoma department of Sun Yat-sen University Cancer Center. Dr.Liu obtained her PhD in Medicine at Sun Yat-sen University of Medical Sciences, P. R. China in 2020. She has been engaged in clinical diagnosis and treatment of nasopharyngeal carcinoma since 2020 and she participated several prospective randomized controlled clinical trials. She has chaired National Natural Science Foundation of China Youth Science Foundation Project and Guangdong Province Science and technology projects, participated in several National Natural Science Foundations. Dr. Liu has published more than 30 research papers.
Interests
Nasopharyngeal carcinoma therapy (radiotherapy, chemotherapy, targeted therapy) in clinical work and research.
Education
Sep/2009-Jul/2014 Bachelor in Medicine
Southern Medical University of Medical Sciences, Guangzhou, P. R. China
Sep/2014-Sep/2017 Master of Medical Science in Oncology
Sun Yat-sen University of Medical Sciences, Guangzhou, P. R. China
Sep/2017-Sep/2020 Ph. D of Medical Science in Oncology
Sun Yat-sen University of Medical Sciences, Guangzhou, P. R. China
Southern Medical University of Medical Sciences, Guangzhou, P. R. China
Sep/2014-Sep/2017 Master of Medical Science in Oncology
Sun Yat-sen University of Medical Sciences, Guangzhou, P. R. China
Sep/2017-Sep/2020 Ph. D of Medical Science in Oncology
Sun Yat-sen University of Medical Sciences, Guangzhou, P. R. China
Publications
(1) Liu SL, Li XY, Yang JH, , et al. Neoadjuvant and adjuvant toripalimab for locoregionally advanced nasopharyngeal carcinoma: a randomised, single-centre, double-blind, placebo-controlled, phase 2 trial. Lancet Oncol. 2024;25(12):1563-75.
(2) Liu SL; Bian LJ; Liu ZX, et al. Development and validation of the immune signature to predict distant metastasis in patients with nasopharyngealcarcinoma, Journal for ImmunoTherapy of Cancer, 2020, 8(1):e000205
(3) Liu SL, Sun XS, Li XY, et al. The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study. Cancer communications, 2019, 39(1):14
(4) Liu SL; Sun XS, Chen QY, et al. Development and validation of a transcriptomics-based gene signature to predict distant metastasis and guide induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma, European Journal of Cancer, 2022, 163: 26-34
(5) Liu SL, Sun XS, Yan JJ, et al. Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients based on induction chemotherapy response, Radiotherapy and Oncology, 2019, 137: 83-94
(6) Liu LZ, Liu SL, Deng P, et al. Targeting the IRAK1-S100A9 Axis Overcomes Resistance to Paclitaxel in Nasopharyngeal Carcinoma, Cancer Research, 2021, 81: 141325
(7)Sun XS, Liu SL, Liang YJ, et al. The role of capecitabine as maintenance therapy in de novo metastatic nasopharyngeal carcinoma: A propensity score matching study. Cancer Commun (Lond). 2020 Jan;40(1):32-42.
(8)Liu LZ, Deng P, Liu SL, et al. Enhancer remodeling activates NOTCH3 signaling to confer chemoresistance in advanced nasopharyngeal carcinoma. Cell Death Dis 2023 Aug 10;14(8)
(9)Lu ZJ, Liu T, Lin JY, Pei ST, Guo L, Liu SL, Mai HQ, Identifying the prognostic value of MRI-based tumor response and predicting the risk of radio-resistance in re-radiotherapy for locally recurrent nasopharyngeal carcinoma. Radiother Oncol. 2023 Mar 23;183:109635.
(10)Sun XS, Xiao ZW, Liu SL, et al. Nasopharyngeal necrosis contributes to overall survival in nasopharyngeal carcinoma without distant metastasis: a comprehensive nomogram model. Eur Radiol 2023 Feb 03
(11) Mao JR, Lan KQ, Liu SL, et al. Can the prognosis of individual patients with nasopharyngeal carcinoma be predicted using a routine blood test at admission? Radiother Oncol. 2023 Feb;179:109445.
(2) Liu SL; Bian LJ; Liu ZX, et al. Development and validation of the immune signature to predict distant metastasis in patients with nasopharyngealcarcinoma, Journal for ImmunoTherapy of Cancer, 2020, 8(1):e000205
(3) Liu SL, Sun XS, Li XY, et al. The diagnostic and prognostic values of plasma Epstein-Barr virus DNA for residual cervical lymphadenopathy in nasopharyngeal carcinoma patients: a retrospective study. Cancer communications, 2019, 39(1):14
(4) Liu SL; Sun XS, Chen QY, et al. Development and validation of a transcriptomics-based gene signature to predict distant metastasis and guide induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma, European Journal of Cancer, 2022, 163: 26-34
(5) Liu SL, Sun XS, Yan JJ, et al. Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients based on induction chemotherapy response, Radiotherapy and Oncology, 2019, 137: 83-94
(6) Liu LZ, Liu SL, Deng P, et al. Targeting the IRAK1-S100A9 Axis Overcomes Resistance to Paclitaxel in Nasopharyngeal Carcinoma, Cancer Research, 2021, 81: 141325
(7)Sun XS, Liu SL, Liang YJ, et al. The role of capecitabine as maintenance therapy in de novo metastatic nasopharyngeal carcinoma: A propensity score matching study. Cancer Commun (Lond). 2020 Jan;40(1):32-42.
(8)Liu LZ, Deng P, Liu SL, et al. Enhancer remodeling activates NOTCH3 signaling to confer chemoresistance in advanced nasopharyngeal carcinoma. Cell Death Dis 2023 Aug 10;14(8)
(9)Lu ZJ, Liu T, Lin JY, Pei ST, Guo L, Liu SL, Mai HQ, Identifying the prognostic value of MRI-based tumor response and predicting the risk of radio-resistance in re-radiotherapy for locally recurrent nasopharyngeal carcinoma. Radiother Oncol. 2023 Mar 23;183:109635.
(10)Sun XS, Xiao ZW, Liu SL, et al. Nasopharyngeal necrosis contributes to overall survival in nasopharyngeal carcinoma without distant metastasis: a comprehensive nomogram model. Eur Radiol 2023 Feb 03
(11) Mao JR, Lan KQ, Liu SL, et al. Can the prognosis of individual patients with nasopharyngeal carcinoma be predicted using a routine blood test at admission? Radiother Oncol. 2023 Feb;179:109445.